vs
Side-by-side financial comparison of AerSale Corp (ASLE) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $90.9M, roughly 2.0× AerSale Corp). AerSale Corp runs the higher net margin — 5.9% vs 1.6%, a 4.3% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -4.0%). Over the past eight quarters, AerSale Corp's revenue compounded faster (0.2% CAGR vs -0.2%).
AerSale, Inc. is a Doral, Florida-based global supplier of aftermarket commercial jet aircraft, engines, used materials, and aeronautical engineering services to passenger and cargo airlines, government, multinational original equipment manufacturers, and independent MROs. AerSale is a member of the Aircraft Fleet Recycling Association.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ASLE vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $90.9M | $177.4M |
| Net Profit | $5.4M | $2.9M |
| Gross Margin | 34.1% | — |
| Operating Margin | 7.8% | 3.9% |
| Net Margin | 5.9% | 1.6% |
| Revenue YoY | -4.0% | 5.0% |
| Net Profit YoY | 99.7% | — |
| EPS (diluted) | $0.10 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $90.9M | $196.9M | ||
| Q3 25 | $71.2M | $179.5M | ||
| Q2 25 | $107.4M | $181.1M | ||
| Q1 25 | $65.8M | $168.9M | ||
| Q4 24 | $94.7M | $187.3M | ||
| Q3 24 | $82.7M | $168.6M | ||
| Q2 24 | $77.1M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $5.4M | — | ||
| Q3 25 | $-120.0K | $5.4M | ||
| Q2 25 | $8.6M | $-4.8M | ||
| Q1 25 | $-5.3M | $4.8M | ||
| Q4 24 | $2.7M | — | ||
| Q3 24 | $509.0K | $-143.5M | ||
| Q2 24 | $-3.6M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 34.1% | 79.5% | ||
| Q3 25 | 30.2% | 80.9% | ||
| Q2 25 | 32.9% | 77.4% | ||
| Q1 25 | 27.3% | 79.7% | ||
| Q4 24 | 31.4% | 78.7% | ||
| Q3 24 | 28.6% | 76.9% | ||
| Q2 24 | 28.2% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 7.8% | 1.2% | ||
| Q3 25 | 4.0% | 3.5% | ||
| Q2 25 | 11.7% | 4.7% | ||
| Q1 25 | -10.1% | 1.2% | ||
| Q4 24 | 5.2% | 13.2% | ||
| Q3 24 | 2.4% | -82.8% | ||
| Q2 24 | -2.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 5.9% | — | ||
| Q3 25 | -0.2% | 3.0% | ||
| Q2 25 | 8.0% | -2.7% | ||
| Q1 25 | -8.0% | 2.8% | ||
| Q4 24 | 2.9% | — | ||
| Q3 24 | 0.6% | -85.1% | ||
| Q2 24 | -4.7% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.10 | $0.05 | ||
| Q3 25 | $0.00 | $0.12 | ||
| Q2 25 | $0.18 | $-0.11 | ||
| Q1 25 | $-0.10 | $0.10 | ||
| Q4 24 | $0.05 | $0.38 | ||
| Q3 24 | $0.01 | $-3.11 | ||
| Q2 24 | $-0.07 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $144.3M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $424.4M | $653.9M |
| Total Assets | $640.5M | $1.2B |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $4.4M | $238.4M | ||
| Q3 25 | $5.3M | $246.3M | ||
| Q2 25 | $5.7M | $445.9M | ||
| Q1 25 | $4.7M | $493.6M | ||
| Q4 24 | $4.7M | $484.6M | ||
| Q3 24 | $9.8M | $453.8M | ||
| Q2 24 | $4.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.3M | $372.2M | ||
| Q3 25 | $1.5M | $376.7M | ||
| Q2 25 | $907.0K | $580.5M | ||
| Q1 25 | $1.1M | $583.4M | ||
| Q4 24 | $1.2M | $585.3M | ||
| Q3 24 | $376.0K | — | ||
| Q2 24 | $522.0K | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $424.4M | $693.1M | ||
| Q3 25 | $417.1M | $727.2M | ||
| Q2 25 | $415.9M | $757.8M | ||
| Q1 25 | $406.5M | $798.5M | ||
| Q4 24 | $455.6M | $778.3M | ||
| Q3 24 | $451.5M | $749.6M | ||
| Q2 24 | $449.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $640.5M | $1.3B | ||
| Q3 25 | $646.3M | $1.3B | ||
| Q2 25 | $646.7M | $1.5B | ||
| Q1 25 | $646.1M | $1.6B | ||
| Q4 24 | $604.7M | $1.6B | ||
| Q3 24 | $601.5M | $1.5B | ||
| Q2 24 | $598.7M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | 0.54× | ||
| Q3 25 | 0.00× | 0.52× | ||
| Q2 25 | 0.00× | 0.77× | ||
| Q1 25 | 0.00× | 0.73× | ||
| Q4 24 | 0.00× | 0.75× | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.4M | — |
| Free Cash FlowOCF − Capex | $9.8M | — |
| FCF MarginFCF / Revenue | 10.8% | — |
| Capex IntensityCapex / Revenue | 1.7% | — |
| Cash ConversionOCF / Net Profit | 2.11× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-29.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $11.4M | $43.7M | ||
| Q3 25 | $-8.9M | $60.8M | ||
| Q2 25 | $19.8M | $12.0M | ||
| Q1 25 | $-45.2M | $35.5M | ||
| Q4 24 | $37.5M | $33.1M | ||
| Q3 24 | $10.4M | $53.9M | ||
| Q2 24 | $-15.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $9.8M | $43.5M | ||
| Q3 25 | $-9.8M | $57.0M | ||
| Q2 25 | $18.6M | $9.3M | ||
| Q1 25 | $-47.6M | $26.9M | ||
| Q4 24 | $32.3M | $31.0M | ||
| Q3 24 | $8.9M | $49.8M | ||
| Q2 24 | $-18.9M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 10.8% | 22.1% | ||
| Q3 25 | -13.8% | 31.7% | ||
| Q2 25 | 17.3% | 5.1% | ||
| Q1 25 | -72.4% | 15.9% | ||
| Q4 24 | 34.0% | 16.6% | ||
| Q3 24 | 10.7% | 29.6% | ||
| Q2 24 | -24.6% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 1.7% | 0.1% | ||
| Q3 25 | 1.3% | 2.2% | ||
| Q2 25 | 1.1% | 1.5% | ||
| Q1 25 | 3.7% | 5.1% | ||
| Q4 24 | 5.6% | 1.1% | ||
| Q3 24 | 1.9% | 2.4% | ||
| Q2 24 | 4.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.11× | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | 2.31× | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | 13.89× | — | ||
| Q3 24 | 20.52× | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASLE
| Products | $57.8M | 64% |
| Maintenance | $23.2M | 26% |
| Leasing Arrangements | $9.9M | 11% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
